Reply to: “Prediction of HBsAg loss after cessation of entecavir therapy”

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Journal of Hepatology Pub Date : 2024-11-06 DOI:10.1016/j.jhep.2024.10.041

Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen

{"title":"Reply to: “Prediction of HBsAg loss after cessation of entecavir therapy”","authors":"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen","doi":"10.1016/j.jhep.2024.10.041","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>AUTHOR CONTRIBUTIONS</h2>RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.</section></section><section><section><h2>DISCLOSURES/ CONFLICT OF INTEREST STATEMENT</h2>MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.</section></section><section><section><h2>DATA AVAILABILITY STATEMENT</h2>The data from this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Funding</h2>Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.041","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

AUTHOR CONTRIBUTIONS

RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.

DISCLOSURES/ CONFLICT OF INTEREST STATEMENT

MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.

DATA AVAILABILITY STATEMENT

The data from this study is available from the corresponding author upon reasonable request.

Funding

Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

答复"恩替卡韦治疗停止后 HBsAg 消失的预测"

章节片段作者贡献RWH Hui参与了手稿的设计和起草。LY Mak 参与了稿件的重要修改。MF Yuen 参与了稿件的关键修改和整个研究的监督。作者声明：他们参与了手稿的准备工作，并审阅和批准了最终版本。声明/利益冲突声明MF Yuen 是艾伯维、Arbutus Biopharma、Assembly Biosciences、Bristol Myer Squibb、Dicerna Pharmaceuticals、葛兰素史克、吉利德科学、杨森、默克夏普和多美、Clear B Therapeutics、Springbank Pharmaceuticals 的顾问委员会成员和/或接受其研究资助；并接受 Arrowhead Pharmaceuticals、Fujirebio Incorporation 和 Sysmex Corporation 的研究资助。其余作者无利益冲突。数据提供声明本研究的数据可向相应作者索取。资助者没有参与研究设计、数据收集/分析/解释、手稿撰写或决定将文章提交发表。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.